Cosmos Health Reports FY24 Revenue $54.34M Up From $53.38M YoY
Benzinga
17 Apr
Full Year 2024 Financial Highlights
Income Statement:
FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gains recognized in the prior year.
Revenue increased by 2.0% to $54.43 million in FY 2024, from $53.38 million in the prior year, driven primarily by sustained organic growth and continued contributions from prior acquisitions.
Gross margin was 7.92%, compared to 8.15% in FY 2023, reflecting a greater mix of revenue from the lower-margin logistics distribution segment.
Total operating expenses declined by 24.16% to $19.86 million, compared to $26.18 million in FY 2023. This includes:
40.26% reduction in general and administrative expenses.
71% decrease in sales and marketing expenses, following a strategic reduction in promotional spend.
Total other income, net, was a loss of $0.64 million in FY 2024, compared to income of $3.29 million in FY 2023. The year-over-year decline was primarily due to the absence of non-cash gains recognized in the prior year, including:
$1.91 million gain on debt extinguishment.
$1.44 million bargain purchase gain related to the acquisition of Cana Laboratories.
Adjusted EBITDA was negative $3.73 million, compared to positive $0.06 million in FY 2023, while Adjusted net loss widened to $4.74 million from $0.81 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.